Mucosat, ointment 5% 30 g

Mucosat^® normalizes the metabolism in the hyaline tissue, stimulates regeneration (restoration) processes in the articular cartilage, has analgesic and anti-inflammatory effects, slows the progression of osteoarthritis and osteochondrosis.

Mucosat ^® contains chondroitin sulfate derived from bovine tissue. Chondroitin sulfate is a high molecular weight mucopolysaccharide and is an essential component of cartilage and ligamentous tissue.

Mucosat^® has chondroprotective and anti-inflammatory activity: it stimulates the synthesis of proteoglycans and cartilage tissue regeneration; inhibits degeneration processes by inhibiting lysosomal enzymes, reducing the activity of superoxide radicals and inflammatory mediators; improves calcium-phosphorus metabolism.

Dimethylsulfoxide in Mucosat^® enhances anti-inflammatory and analgesic effects. With its transport properties it increases the degree of absorption of the active substance.

Inclusion of the drug in the regimen of complex therapy promotes a rapid reduction of swelling and pain and increases joint mobility.

Pharmacokinetics

In accordance with the data obtained in experimental studies on mice using radiolabeled ³H-chondroitin sulfate, the absorption rate of chondroitin sulfate is 14%.

Chondroitin sulfate after application to the skin is rapidly and selectively delivered to the joint with reaching C_max after 30 minutes and subsequent biphasic elimination of the drug from the cartilage. Completion of the fast excretion phase occurs 1 h after application. Retention time of the drug in the joint is 5 h.

Indications

Degenerative-dystrophic diseases of the joints and spine:

• osteoarthritis;
• intervertebral osteochondrosis.

.

Active ingredient

Chondroitin sulfate

Composition

The active ingredient:

chondroitin sulfate sodium in terms of dry substance 0.05 g.

Excipients:

Dimethyl sulfoxide 0.1 g,

Anhydrous lanolin 0.15 g,

Vaseline medical 0.5 g,

purified water up to 1 g.

How to take, the dosage

Outwardly. The ointment is applied in a thin layer to the skin over the lesion 2-3 times a day and rubbed for 2-3 minutes until completely absorbed.

The course of treatment is 2-3 weeks. The course of treatment is repeated if necessary.

Interaction

Cases of interaction or incompatibility with other drugs have not been described.

Special Instructions

Avoid contact of the drug with mucous membranes and open wounds.

Do not use the drug without consulting a physician during pregnancy, while breastfeeding and in children.

Impact on the ability to drive vehicles and operate machinery

The drug does not affect the ability to drive vehicles, operate machinery and engage in other activities requiring increased attention and quick psychomotor reaction.

Contraindications

• high sensitivity to the ingredients of the drug
• damage of the integrity of the skin in the areas where the drug is supposed to be applied.

With caution: pregnancy, breast-feeding, age under 18 years (effectiveness and safety is not established).

Side effects

Allergic reactions are possible.

Pregnancy use

Due to the lack of safety data on the use of the drug during pregnancy, the use of the drug during this period is possible only if the estimated benefit to the mother exceeds the potential risk to the fetus.

There are no clinical data on the use of the drug in women during breastfeeding.

Similarities

Chondroxid, Chondrolon, Chondroitin-ACOS, Chondrogard, Arthradol, Chondroitin, Injectran, Artogistan